The direct oral anticoagulants (DOACs) are drugs used in clinical practice since 2009 for the prevention of stroke or systemic embolism in non-valvular atrial fibrillation, and for the treatment and secondary prevention of venous thromboembolism. The four DOACs, including the three factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and one direct thrombin inhibitor (dabigatran) provide oral anticoagulation therapy alternatives to Vitamin K antagonists (VKAs). Despite their clear advantages, the DOACs require on the part of the internist a thorough knowledge of their pharmacokinetic and pharmacodynamic characteristics to ensure their correct use, laboratory monitoring and the appropriate management of adverse events. This document represents a consensus paper on the use of DOACs by representatives of three Italian scientific societies: the Italian Society of Internal Medicine (SIMI), the Federation of the Associations of Hospital Managers (FADOI), and the Society for the Study of Haemostasis and Thrombosis (SISET). This document formulates expert opinion guidance for pragmatic managing, monitoring and reversing the anticoagulant effect of DOACs in both chronic and emergency settings. This practical guidance may help the internist to create adequate protocols for patients hospitalized ion internal medicine wards, where patients are often elderly subjects affected by poly-morbidities and renal insufficiency, and, thus, require particular attention to drug–drug interactions and peri-procedural protocols.

Italian intersociety consensus on DOAC use in internal medicine / Prisco, D.; Ageno, W.; Becattini, C.; D'Angelo, A.; Davi, G.; De Cristofaro, R.; Dentali, F.; Di Minno, G.; Falanga, A.; Gussoni, G.; Masotti, L.; Palareti, G.; Pignatelli, P.; Santi, R. M.; Santilli, F.; Silingardi, M.; Tufano, A.; Violi, F.. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1828-0447. - 12:3(2017), pp. 387-406. [10.1007/s11739-017-1628-6]

Italian intersociety consensus on DOAC use in internal medicine

Pignatelli P.
;
Violi F.
Ultimo
2017

Abstract

The direct oral anticoagulants (DOACs) are drugs used in clinical practice since 2009 for the prevention of stroke or systemic embolism in non-valvular atrial fibrillation, and for the treatment and secondary prevention of venous thromboembolism. The four DOACs, including the three factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) and one direct thrombin inhibitor (dabigatran) provide oral anticoagulation therapy alternatives to Vitamin K antagonists (VKAs). Despite their clear advantages, the DOACs require on the part of the internist a thorough knowledge of their pharmacokinetic and pharmacodynamic characteristics to ensure their correct use, laboratory monitoring and the appropriate management of adverse events. This document represents a consensus paper on the use of DOACs by representatives of three Italian scientific societies: the Italian Society of Internal Medicine (SIMI), the Federation of the Associations of Hospital Managers (FADOI), and the Society for the Study of Haemostasis and Thrombosis (SISET). This document formulates expert opinion guidance for pragmatic managing, monitoring and reversing the anticoagulant effect of DOACs in both chronic and emergency settings. This practical guidance may help the internist to create adequate protocols for patients hospitalized ion internal medicine wards, where patients are often elderly subjects affected by poly-morbidities and renal insufficiency, and, thus, require particular attention to drug–drug interactions and peri-procedural protocols.
2017
atrial fibrillation; direct oral anticoagulant; drug interactions; elderly; internist; novel oral anticoagulant; pulmonary embolism; venous thromboembolism; venous thrombosis; administration, oral; anticoagulants; antithrombins; atrial fibrillation; clinical competence; consensus; dabigatran; drug-related side effects and adverse reactions; factor xa inhibitors; food-drug interactions; humans; internal medicine; italy; liver diseases; perioperative period; pyrazoles; pyridines; pyridones; rivaroxaban; stroke; thiazoles; time factors; venous thromboembolism
01 Pubblicazione su rivista::01a Articolo in rivista
Italian intersociety consensus on DOAC use in internal medicine / Prisco, D.; Ageno, W.; Becattini, C.; D'Angelo, A.; Davi, G.; De Cristofaro, R.; Dentali, F.; Di Minno, G.; Falanga, A.; Gussoni, G.; Masotti, L.; Palareti, G.; Pignatelli, P.; Santi, R. M.; Santilli, F.; Silingardi, M.; Tufano, A.; Violi, F.. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1828-0447. - 12:3(2017), pp. 387-406. [10.1007/s11739-017-1628-6]
File allegati a questo prodotto
File Dimensione Formato  
Prisco_Italian-Intersociety_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 614.99 kB
Formato Adobe PDF
614.99 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1388210
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 45
social impact